| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Mepazine (5–20 μM; 4 days) dramatically reduces the viability of activated B-cell subtypes of diffuse large B-cell lymphoma (ABCDLBCL) cells, but has no effect on GCB-DLBCL cells [1].
|
|---|---|
| ln Vivo |
Using a murine DLBCL xenograft tumor model, mepazine (16 mg/kg; i.p.) inhibits growth and causes apoptosis in the ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rgnull (NSG) mice. Expanding the ABC-DLBCL cell line OCI-Ly10 is significantly hindered by the daily treatment of mepazine [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: ABC-DLBCL cell line (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell line (BJAB, Su-DHL-6, Su-DHL-4) Tested Concentrations: 5, 10 and 20 μM Incubation Duration: 4 days Experimental Results: Caused a decrease in the viability of HBL1, OCI-Ly3, U2932 and TMD8 cells in ABC-DLBCL cells, but had no significant effect on GCB-DLBCL cells. |
| Animal Protocol |
Animal/Disease Models: 6 to 8 weeks old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with murine DLBCL xenogeneic tumor model [1]
Doses: 400 μg per animal (25 g), equivalent to approximately 16 mg/ Kilogram. Mode of Route of Administration: intraperitonealadministration; continuous administration every 24 hrs (hrs (hours)) starting 1 or 12 days after transplantation; Daily administration Experimental Results: Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10. |
| References |
[1]. Nagel D, et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell. 2012 Dec 11;22(6):825-37.
|
| Molecular Formula |
C19H22N2S
|
|---|---|
| Molecular Weight |
310.46
|
| Exact Mass |
310.1504
|
| CAS # |
60-89-9
|
| Related CAS # |
Mepazine hydrochloride;2975-36-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CN1CCCC(CN2C3=C(C=CC=C3)SC3C2=CC=CC=3)C1
|
| Synonyms |
P-391; P 391; Pecazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~322.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (16.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (16.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2210 mL | 16.1051 mL | 32.2103 mL | |
| 5 mM | 0.6442 mL | 3.2210 mL | 6.4421 mL | |
| 10 mM | 0.3221 mL | 1.6105 mL | 3.2210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
